Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).

被引：0
作者：
Thein, Wai Lin
Tun, Aung
Thein, Kyaw Zin
Guevara, Elizabeth
机构：
[1] Univ Med, Brooklyn, NY USA
[2] Brooklyn Hosp Ctr, Brooklyn, NY USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e20558
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20558
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Gefitinib Compared with Systemic Chemotherapy as First-line Treatment for Chemotherapy-naive Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of Randomised Controlled Trials
    Wang, F.
    Wang, L. D.
    Li, B.
    Sheng, Z. X.
    CLINICAL ONCOLOGY, 2012, 24 (06) : 396 - 401
  • [32] Comparative effectiveness of immune-checkpoint inhibitors as first-line treatment for advanced nonsquamous non-small cell lung cancer patients: A network meta-analysis and a systematic review.
    Bitton, Roberto Jorge
    Jacob, Natalia
    Carrera, Juan Manuel
    Perez, Ezequiel Cayetano
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Can meta-analysis suggest carboplatin/paclitaxel as a reference arm in randomized trials of first-line chemotherapy for advanced non-small cell lung cancer?
    Yamanaka, T.
    Yamamoto, N.
    Seto, T.
    Takahashi, T.
    Murakami, H.
    Tsuya, A.
    Naito, T.
    Kaira, K.
    Nakamura, Y.
    Ichinose, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] The role of immune checkpoint inhibitors in the first-line treatment for patients with advanced biliary tract cancer: a systematic review and meta-analysis of randomized trials
    Vitale, Elsa
    Rizzo, Alessandro
    Maistrello, Lorenza
    Nardulli, Patrizia
    Talienti, Tiziana
    Quaresmini, Davide
    De Summa, Simona
    Massafra, Raffaella
    Silvestris, Nicola
    Brunetti, Oronzo
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [35] First-line treatments for advanced non-squamous non-small cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a systematic review, network meta-analysis, and cost-effectiveness analysis
    Tian, Wentao
    Niu, Lishui
    Shi, Yin
    Li, Shuishi
    Zhou, Rongrong
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [36] Nintedanib in Combination With Chemotherapy in the Treatment of Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Alhadeethi, Abdulhameed
    Awwad, Sara Adel
    Abed, Mohamed
    Amin, Ahmed Mostafa
    Aboelkhier, Menna M.
    Yassin, Mazen Negmeldin Aly
    Morsi, Maha H.
    Kashbour, Muataz Omar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (02)
  • [37] Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis
    Chen, Ching-Yi
    Huang, Chi-Hsien
    Chen, Wang-Chun
    Huang, Ming-Shyan
    Wei, Yu-Feng
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 108
  • [38] Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer
    Remon, Jordi
    Besse, Benjamin
    CURRENT OPINION IN ONCOLOGY, 2017, 29 (02) : 97 - 104
  • [39] Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis
    Li, Dan-Ni
    Lu, Wen-Qing
    Yang, Bo-Wen
    Zhang, Ling-Yun
    Jin, Bo
    Wang, Shuo
    Che, Xiao-Fang
    Li, Ce
    Liu, Yun-Peng
    Qu, Xiu-Juan
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [40] Efficacy and safety of anlotinib in combination with immune checkpoint inhibitors or not as advanced non-small cell lung cancer treatment: a systematic review and network meta-analysis
    Wu, Zhengyu
    Zhou, Peng
    Zhao, Yanan
    Wang, Junping
    Gao, Shan
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (05) : 2451 - 2463
12345